Eligibility Leukemia NCT01421862

  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT01421862
Criteria
Descrição

Criteria

samples from previously untreated non-m3 acute myeloid leukemia (aml)
Descrição

Specimen AML Untreated | Exception Acute Promyelocytic Leukemia

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0370003
UMLS CUI [1,2]
C0023467
UMLS CUI [1,3]
C0332155
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0023487
normal karyotype (nk) intermediate-risk disease
Descrição

Normal karyotype | Disease Intermediate Risk

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0333684
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C3640764
two or more vials of cryopreserved pretreatment bone marrow cells and/or two or more vials of cryopreserved pretreatment blood cells available from the intergroup aml repository
Descrição

Bone Marrow Cells Pretreatment Cryopreserved | Blood Cells Pretreatment Cryopreserved

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0005955
UMLS CUI [1,2]
C3539075
UMLS CUI [1,3]
C0010405
UMLS CUI [2,1]
C0005773
UMLS CUI [2,2]
C3539075
UMLS CUI [2,3]
C0010405
blast count ≥ 60%
Descrição

Blast count

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0523113
eligible and evaluable for the patient's clinical trial, and did not have fatal induction toxicity
Descrição

Eligibility Clinical Trial | Evaluable Patient Clinical Trial | Toxicity Fatal Absent

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1548635
UMLS CUI [1,2]
C0008976
UMLS CUI [2,1]
C2986511
UMLS CUI [2,2]
C0008976
UMLS CUI [3,1]
C0600688
UMLS CUI [3,2]
C1302234
UMLS CUI [3,3]
C0332197
response to protocol induction chemotherapy:
Descrição

Response Induction Chemotherapy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1704632
UMLS CUI [1,2]
C3179010
non-response: aml with failure to achieve a complete remission (cr) after induction chemotherapy ("7 & 3"-based therapy using cytatabine and/or daunorobicin hydrochloride (dnr) or idarubicin and/or dnr
Descrição

Therapy non-responder | Complete remission failed | Status post Induction Chemotherapy | Cytarabine | Daunorubicin Hydrochloride | Idarubicin

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0919875
UMLS CUI [2,1]
C0677874
UMLS CUI [2,2]
C0231175
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C3179010
UMLS CUI [4]
C0010711
UMLS CUI [5]
C0282123
UMLS CUI [6]
C0020789
responders: continued complete remission (ccr) > 2 years
Descrição

Therapy responder | Continued Complete Response

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0919876
UMLS CUI [2]
C2347861
patient characteristics:
Descrição

Patient Characteristics

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0815172
not specified
Descrição

Unspecified

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0205370
prior concurrent therapy:
Descrição

Prior Therapy Concurrent

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0205420
see disease characteristics
Descrição

ID.12

Tipo de dados

boolean

Similar models

Eligibility Leukemia NCT01421862

  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT01421862
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Specimen AML Untreated | Exception Acute Promyelocytic Leukemia
Item
samples from previously untreated non-m3 acute myeloid leukemia (aml)
boolean
C0370003 (UMLS CUI [1,1])
C0023467 (UMLS CUI [1,2])
C0332155 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0023487 (UMLS CUI [2,2])
Normal karyotype | Disease Intermediate Risk
Item
normal karyotype (nk) intermediate-risk disease
boolean
C0333684 (UMLS CUI [1])
C0012634 (UMLS CUI [2,1])
C3640764 (UMLS CUI [2,2])
Bone Marrow Cells Pretreatment Cryopreserved | Blood Cells Pretreatment Cryopreserved
Item
two or more vials of cryopreserved pretreatment bone marrow cells and/or two or more vials of cryopreserved pretreatment blood cells available from the intergroup aml repository
boolean
C0005955 (UMLS CUI [1,1])
C3539075 (UMLS CUI [1,2])
C0010405 (UMLS CUI [1,3])
C0005773 (UMLS CUI [2,1])
C3539075 (UMLS CUI [2,2])
C0010405 (UMLS CUI [2,3])
Blast count
Item
blast count ≥ 60%
boolean
C0523113 (UMLS CUI [1])
Eligibility Clinical Trial | Evaluable Patient Clinical Trial | Toxicity Fatal Absent
Item
eligible and evaluable for the patient's clinical trial, and did not have fatal induction toxicity
boolean
C1548635 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C2986511 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C0600688 (UMLS CUI [3,1])
C1302234 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
Response Induction Chemotherapy
Item
response to protocol induction chemotherapy:
boolean
C1704632 (UMLS CUI [1,1])
C3179010 (UMLS CUI [1,2])
Therapy non-responder | Complete remission failed | Status post Induction Chemotherapy | Cytarabine | Daunorubicin Hydrochloride | Idarubicin
Item
non-response: aml with failure to achieve a complete remission (cr) after induction chemotherapy ("7 & 3"-based therapy using cytatabine and/or daunorobicin hydrochloride (dnr) or idarubicin and/or dnr
boolean
C0919875 (UMLS CUI [1])
C0677874 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C3179010 (UMLS CUI [3,2])
C0010711 (UMLS CUI [4])
C0282123 (UMLS CUI [5])
C0020789 (UMLS CUI [6])
Therapy responder | Continued Complete Response
Item
responders: continued complete remission (ccr) > 2 years
boolean
C0919876 (UMLS CUI [1])
C2347861 (UMLS CUI [2])
Patient Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Unspecified
Item
not specified
boolean
C0205370 (UMLS CUI [1])
Prior Therapy Concurrent
Item
prior concurrent therapy:
boolean
C1514463 (UMLS CUI [1,1])
C0205420 (UMLS CUI [1,2])
ID.12
Item
see disease characteristics
boolean